Orris

7:3 reversal for extubations

Reading File
Finding Sources
Finding Sources
Searching the Web

7:3 reversal extubation neostigmine atropine glycopyrrolate ratio anesthesia

Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Here is a thorough breakdown of the 7:3 reversal concept for extubation:

"7:3 Reversal" for Extubation

This refers to the neostigmine–atropine dose combination used to reverse non-depolarizing neuromuscular blockade (NMB) before extubation:
  • Neostigmine 0.07 mg/kg + Atropine 0.03 mg/kg
The ratio of 7 (neostigmine) to 3 (atropine) reflects the approximate dose proportions when both are given together in weight-based dosing. This is a practical bedside shorthand, particularly common in teaching environments.

Why the Combination is Needed

Neostigmine is an anticholinesterase - it prevents breakdown of acetylcholine at the neuromuscular junction, thereby reversing the competitive block of non-depolarizing relaxants (rocuronium, vecuronium, atracurium, cisatracurium). However, by raising acetylcholine systemically, it also stimulates muscarinic receptors, causing:
  • Bradycardia
  • Increased salivation and secretions
  • Increased bowel motility
  • Bronchoconstriction
An anticholinergic (atropine or glycopyrrolate) is therefore co-administered to block these muscarinic side effects - Barash's Clinical Anesthesia, 9e, p. 1655.

Two Standard Reversal Pairings

AnticholinesteraseAnticholinergicRatio / Dose
NeostigmineAtropineNeostigmine 0.04-0.07 mg/kg + Atropine ~0.02 mg/kg (roughly 7:3 or 2:1)
NeostigmineGlycopyrrolate0.2 mg glycopyrrolate per 1 mg neostigmine (1:5 ratio)

Atropine vs Glycopyrrolate - Which to Use With Neostigmine?

Glycopyrrolate is preferred when pairing with neostigmine because:
  • Its onset and offset times are similar to neostigmine (matched kinetics = more stable HR)
  • Atropine has a faster onset, causes more tachycardia, and crosses the blood-brain barrier (CNS effects)
  • Glycopyrrolate dose = one-fifth that of neostigmine (0.2 mg glycopyrrolate per 1 mg neostigmine)
  • Barash Clinical Anesthesia, 9e; Mulholland & Greenfield's Surgery, 7e, p. 792
The 7:3 combination (neostigmine + atropine) remains widely used in many institutions due to historical practice and atropine availability.

Neostigmine Dosing Principles

  • Standard dose: 0.04-0.07 mg/kg IV (max 5 mg total)
  • Doses >0.07-0.14 mg/kg produce a ceiling effect - no additional reversal, only more side effects
  • Must not be given at profound block (TOF count 0 or 1) - wait for at least 2-3 twitches (TOF count ≥2, ideally ≥3-4)
  • Goal: TOF ratio ≥0.9 before extubation
  • Neostigmine given after full recovery (TOF ≥0.9) can paradoxically cause weakness (depolarizing-like block from excess acetylcholine) - Barash, 9e

Limitations of Neostigmine Reversal

  • Residual block is common even after neostigmine - studies show ~58% of patients had TOF <0.9 at extubation despite reversal use (Miller's Anesthesia, 10e)
  • It cannot reliably reverse deep block (TOF count 0-1)
  • Volatile anesthetics, magnesium, hypothermia, and age all reduce its efficacy

Sugammadex: The Modern Alternative

Sugammadex (2-16 mg/kg depending on block depth) selectively encapsulates rocuronium/vecuronium and reverses even profound block within 2-3 minutes, without requiring any anticholinergic co-administration. It has largely replaced neostigmine at many centers for steroidal NMBAs.
Bottom line: The "7:3 reversal" is shorthand for neostigmine 0.07 mg/kg + atropine 0.03 mg/kg given together at end of surgery to reverse non-depolarizing NMB before extubation. Glycopyrrolate (at 1:5 ratio with neostigmine by weight) is pharmacologically the better-matched anticholinergic partner, but atropine in the 7:3 combination remains a standard in many settings.
This is a shared conversation. Sign in to Orris to start your own chat.